# Relmacabtagene Autoleucel in Patients With LBCL

> **NCT06142175** · — · UNKNOWN · sponsor: **Shanghai Ming Ju Biotechnology Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Large B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** Relmacabtagene Autoleucel

## Key facts

- **NCT ID:** NCT06142175
- **Lead sponsor:** Shanghai Ming Ju Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-28
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06142175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06142175, "Relmacabtagene Autoleucel in Patients With LBCL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06142175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*